Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Month-of-birth-effect in multiple sclerosis in Austria.

Walleczek NK, Frommlet F, Bsteh G, Eggers C, Rauschka H, Koppi S, Assar H, Ehling R, Birkl C, Salhofer-Polanyi S, Baumgartner A, Blechinger S, Buchinger D, Sellner J, Kraus J, Moser H, Mayr M, Guger M, Rathmaier S, Raber B, Liendl H, Hiller MS, Parigger S, Morgenstern G, Kempf I, Spiss HK, Meister B, Heine M, Cisar A, Bachler H, Khalil M, Fuchs S, Enzinger C, Fazekas F, Leutmezer F, Berger T, Kristoferitsch W, Aboulenein-Djamshidian F.

Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924. [Epub ahead of print]

PMID:
30463473
2.

Responsiveness and meaningful improvement of mobility measures following MS rehabilitation.

Baert I, Smedal T, Kalron A, Rasova K, Heric-Mansrud A, Ehling R, Elorriaga Minguez I, Nedeljkovic U, Tacchino A, Hellinckx P, Adriaenssens G, Stachowiak G, Gusowski K, Cattaneo D, Borgers S, Hebert J, Dalgas U, Feys P.

Neurology. 2018 Nov 13;91(20):e1880-e1892. doi: 10.1212/WNL.0000000000006532. Epub 2018 Oct 17.

PMID:
30333161
3.

Improvement of medical judgments by numerical training in patients with multiple sclerosis.

Zamarian L, Delazer M, Ehling R, Pertl MT, Bsteh G, Wenter J, Glatzl S, Brenneis C, Benke T, Berger T.

Eur J Neurol. 2019 Jan;26(1):106-112. doi: 10.1111/ene.13778. Epub 2018 Sep 5.

4.

High Efficiency Gene Correction in Hematopoietic Cells by Donor-Template-Free CRISPR/Cas9 Genome Editing.

Sürün D, Schwäble J, Tomasovic A, Ehling R, Stein S, Kurrle N, von Melchner H, Schnütgen F.

Mol Ther Nucleic Acids. 2018 Mar 2;10:1-8. doi: 10.1016/j.omtn.2017.11.001. Epub 2017 Nov 10.

5.

Successful long-term management of spasticity in patients with multiple sclerosis using a software application (APP): A pilot study.

Ehling R, Edlinger M, Hermann K, Dröge K, Seidinger Y, Miller U, Alber HF, Brenneis C.

Mult Scler Relat Disord. 2017 Oct;17:15-21. doi: 10.1016/j.msard.2017.06.013. Epub 2017 Jun 27.

PMID:
29055449
6.

Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.

Wurth S, Kuenz B, Bsteh G, Ehling R, Di Pauli F, Hegen H, Auer M, Gredler V, Deisenhammer F, Reindl M, Berger T.

PLoS One. 2017 Aug 4;12(8):e0182462. doi: 10.1371/journal.pone.0182462. eCollection 2017.

7.

Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis-The PaSiMS II study.

Bsteh G, Ehling R, Walchhofer LM, Hegen H, Auer M, Wurth S, Di Pauli F, Wagner M, Reindl M, Deisenhammer F, Berger T.

PLoS One. 2017 Jul 27;12(7):e0181458. doi: 10.1371/journal.pone.0181458. eCollection 2017.

8.

Continuous intra-arterial nimodipine infusion in refractory symptomatic vasospasm after subarachnoid hemorrhage.

Helbok R, Zangerle A, Chemelli A, Beer R, Benke T, Ehling R, Fischer M, Sojer M, Pfausler B, Thome C, Schmutzhard E.

Springerplus. 2016 Oct 18;5(1):1807. eCollection 2016.

9.

Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.

Bsteh G, Feige J, Ehling R, Auer M, Hegen H, Di Pauli F, Deisenhammer F, Reindl M, Berger T.

Mult Scler. 2017 Aug;23(9):1241-1248. doi: 10.1177/1352458516675751. Epub 2016 Oct 20.

PMID:
27765877
10.

Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter.

Ehling R, Bsteh G, Di Pauli F, Hegen H, Auer M, Obermair K, Wagner M, Deisenhammer F, Reindl M, Berger T.

Mult Scler Relat Disord. 2016 Sep;9:150-4. doi: 10.1016/j.msard.2016.07.014. Epub 2016 Jul 27.

PMID:
27645364
11.

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.

Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, Deisenhammer F, Reindl M, Berger T.

PLoS One. 2016 Jul 8;11(7):e0158978. doi: 10.1371/journal.pone.0158978. eCollection 2016.

12.

Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.

Ehling R, Di Pauli F, Lackner P, Rainer C, Kraus V, Hegen H, Lutterotti A, Kuenz B, De Zordo T, Schocke M, Glatzl S, Löscher WN, Deisenhammer F, Reindl M, Berger T.

J Neuroimmunol. 2015 Oct 15;287:98-105. doi: 10.1016/j.jneuroim.2015.08.004. Epub 2015 Aug 10.

PMID:
26439969
13.

Damping of monocular pendular nystagmus with vibration in a patient with multiple sclerosis.

Ehling R, Lutterotti A, Brenneis C, Zee DS, Beh SC, Kheradmand A.

Neurology. 2014 Nov 11;83(20):1879. doi: 10.1212/WNL.0000000000000995. No abstract available.

14.

Cerebellar dysfunction in a family harboring the PSEN1 mutation co-segregating with a cathepsin D variant p.A58V.

Ehling R, Nosková L, Stránecký V, Hartmannová H, Přistoupilová A, Hodaňová K, Benke T, Kovacs GG, Ströbel T, Niedermüller U, Wagner M, Nachbauer W, Janecke A, Budka H, Boesch S, Kmoch S.

J Neurol Sci. 2013 Mar 15;326(1-2):75-82. doi: 10.1016/j.jns.2013.01.017. Epub 2013 Feb 13.

PMID:
23415546
15.

Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients.

Schmied MC, Zehetmayer S, Reindl M, Ehling R, Bajer-Kornek B, Leutmezer F, Zebenholzer K, Hotzy C, Lichtner P, Meitinger T, Wichmann HE, Illig T, Gieger C, Huber K, Khalil M, Fuchs S, Schmidt H, Auff E, Kristoferitsch W, Fazekas F, Berger T, Vass K, Zimprich A.

Neurogenetics. 2012 May;13(2):181-7. doi: 10.1007/s10048-012-0316-y. Epub 2012 Mar 14.

PMID:
22411505
16.

Recurrent intracerebral haemorrhage after coitus: a case report of sporadic cerebral amyloid angiopathy in a younger patient.

Ehling R, Helbok R, Beer R, Lackner P, Broessner G, Pfausler B, Röcken C, Aguzzi A, Chemelli A, Schmutzhard E.

Eur J Neurol. 2012 Mar;19(3):e29-31. doi: 10.1111/j.1468-1331.2011.03624.x. No abstract available.

PMID:
22329859
17.

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.

Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M.

J Neuroinflammation. 2011 Dec 28;8:184. doi: 10.1186/1742-2094-8-184.

18.

Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis.

Ehling R, Pauli FD, Lackner P, Kuenz B, Santner W, Lutterotti A, Gneiss C, Hegen H, Schocke M, Deisenhammer F, Berger T, Reindl M.

Fluids Barriers CNS. 2011 Oct 26;8(1):25. doi: 10.1186/2045-8118-8-25.

19.

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

Hegen H, Schleiser M, Gneiss C, Di Pauli F, Ehling R, Kuenz B, Lutterotti A, Berger T, Deisenhammer F.

Mult Scler. 2012 May;18(5):610-5. doi: 10.1177/1352458511426738. Epub 2011 Oct 19.

PMID:
22013146
20.

Olfactory threshold is impaired in early, active multiple sclerosis.

Lutterotti A, Vedovello M, Reindl M, Ehling R, DiPauli F, Kuenz B, Gneiss C, Deisenhammer F, Berger T.

Mult Scler. 2011 Aug;17(8):964-9. doi: 10.1177/1352458511399798. Epub 2011 Mar 3.

PMID:
21372115
21.

Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.

Di Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, Deisenhammer F, Reindl M, Berger T.

Clin Immunol. 2011 Mar;138(3):247-54. doi: 10.1016/j.clim.2010.11.013. Epub 2010 Dec 18.

PMID:
21169067
22.

Selective amygdalo-hippocampectomy as a potential trigger for disease progression in multiple sclerosis.

Ehling R, Dobesberger J, Unterberger I, Benke T, Gotwald T, Ortler M, Berger T, Trinka E.

Clin Neurol Neurosurg. 2011 Feb;113(2):136-8. doi: 10.1016/j.clineuro.2010.08.004. Epub 2010 Dec 18. No abstract available.

PMID:
21168954
23.

Natalizumab treatment reduces endothelial activity in MS patients.

Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F.

J Neuroimmunol. 2010 Oct 8;227(1-2):190-4. doi: 10.1016/j.jneuroim.2010.07.012. Epub 2010 Aug 23.

PMID:
20739072
24.

Anti-alpha B-crystallin immunoreactivity in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.

Hegen H, Wanschitz J, Ehling R, Deisenhammer F, Löscher WN, Reindl M, Berger T.

J Peripher Nerv Syst. 2010 Jun;15(2):150-2. doi: 10.1111/j.1529-8027.2010.00264.x. No abstract available.

PMID:
20626779
25.

A 45-year old male with left-sided hemihypesthesia.

Ehling R, Sterlacci W, Maier H, Berger T.

Brain Pathol. 2010 Mar;20(2):515-8. doi: 10.1111/j.1750-3639.2009.00364.x.

PMID:
20438473
26.

Multiple sclerosis - established and novel therapeutic approaches.

Ehling R, Berger T, Reindl M.

Cent Nerv Syst Agents Med Chem. 2010 Mar;10(1):3-15. Review.

PMID:
20236038
27.

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.

Gneiss C, Koudouovoh-Tripp PM, Ropele S, Gotwald T, Ehling R, Lutterotti A, Aichner F, Ladurner G, Eggers C, Schautzer F, Künz B, Millonig A, Aspeck E, Reindl M, Berger T, Fazekas F, Deisenhammer F.

Mult Scler. 2009 Dec;15(12):1481-8. doi: 10.1177/1352458509347153. Epub 2009 Nov 13.

PMID:
19965519
28.

Features of intrathecal immunoglobulins in patients with multiple sclerosis.

Di Pauli F, Gredler V, Kuenz B, Lutterotti A, Ehling R, Gneiss C, Schocke M, Deisenhammer F, Reindl M, Berger T.

J Neurol Sci. 2010 Jan 15;288(1-2):147-50. doi: 10.1016/j.jns.2009.09.016. Epub 2009 Oct 13.

PMID:
19828154
29.

High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.

Millonig A, Rudzki D, Hölzl M, Ehling R, Gneiss C, Künz B, Berger T, Reindl M, Deisenhammer F.

Mult Scler. 2009 Aug;15(8):977-83. doi: 10.1177/1352458509105384. Epub 2009 May 22.

PMID:
19465447
30.

Intrathecal anti-alphaB-crystallin IgG antibody responses: potential inflammatory markers in Guillain-Barré syndrome.

Wanschitz J, Ehling R, Löscher WN, Künz B, Deisenhammer F, Kuhle J, Budka H, Reindl M, Berger T.

J Neurol. 2008 Jun;255(6):917-24. doi: 10.1007/s00415-008-0815-9. Epub 2008 Jul 11.

PMID:
18712293
31.

Smoking is a risk factor for early conversion to clinically definite multiple sclerosis.

Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, O'Reilly E, Munger K, Deisenhammer F, Ascherio A, Berger T.

Mult Scler. 2008 Sep;14(8):1026-30. doi: 10.1177/1352458508093679. Epub 2008 Jul 16.

PMID:
18632775
32.

Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis.

Kuenz B, Lutterotti A, Ehling R, Gneiss C, Haemmerle M, Rainer C, Deisenhammer F, Schocke M, Berger T, Reindl M.

PLoS One. 2008 Jul 2;3(7):e2559. doi: 10.1371/journal.pone.0002559.

33.

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.

Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, Lutterotti A, Khalil M, Kuenz B, Mayringer I, Reindl M, Berger T, Deisenhammer F.

Mult Scler. 2006 Dec;12(6):731-7.

PMID:
17263000
34.

Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia.

Kamm C, Asmus F, Mueller J, Mayer P, Sharma M, Muller UJ, Beckert S, Ehling R, Illig T, Wichmann HE, Poewe W, Mueller JC, Gasser T.

Neurology. 2006 Nov 28;67(10):1857-9.

PMID:
17130424
35.

Increased serum levels of soluble CD14 indicate stable multiple sclerosis.

Lutterotti A, Kuenz B, Gredler V, Khalil M, Ehling R, Gneiss C, Egg R, Deisenhammer F, Berger T, Reindl M.

J Neuroimmunol. 2006 Dec;181(1-2):145-9. Epub 2006 Oct 13.

PMID:
17046070
36.

Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.

Gneiss C, Tripp P, Ehling R, Khalil M, Lutterotti A, Egg R, Mayringer I, Künz B, Berger T, Reindl M, Deisenhammer F.

J Neuroimmunol. 2006 May;174(1-2):174-9. Epub 2006 Mar 23.

PMID:
16556466
37.

Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments.

Khalil M, Reindl M, Lutterotti A, Kuenz B, Ehling R, Gneiss C, Lackner P, Deisenhammer F, Berger T.

J Neuroimmunol. 2006 May;174(1-2):147-56. Epub 2006 Mar 6.

PMID:
16516980
38.

Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis.

Kuenz B, Lutterotti A, Khalil M, Ehling R, Gneiss C, Deisenhammer F, Reindl M, Berger T.

J Neuroimmunol. 2005 Oct;167(1-2):143-9.

PMID:
16040131
39.

Presence of RHD in serologically D-, C/E+ individuals: a European multicenter study.

Gassner C, Doescher A, Drnovsek TD, Rozman P, Eicher NI, Legler TJ, Lukin S, Garritsen H, Kleinrath T, Egger B, Ehling R, Körmöczi GF, Kilga-Nogler S, Schoenitzer D, Petershofen EK.

Transfusion. 2005 Apr;45(4):527-38.

PMID:
15819673
40.

Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis.

Ehling R, Lutterotti A, Wanschitz J, Khalil M, Gneiss C, Deisenhammer F, Reindl M, Berger T.

Mult Scler. 2004 Dec;10(6):601-6.

PMID:
15584481
41.

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

Gneiss C, Reindl M, Lutterotti A, Ehling R, Egg R, Khalil M, Berger T, Deisenhammer F.

Mult Scler. 2004 Oct;10(5):507-10.

PMID:
15471365
42.

Epitope specificity of neutralizing antibodies against IFN-beta.

Gneiss C, Reindl M, Berger T, Lutterotti A, Ehling R, Egg R, Deisenhammer F.

J Interferon Cytokine Res. 2004 May;24(5):283-90.

PMID:
15153311
43.

Genetic variants in the tumor necrosis factor receptor II gene in patients with multiple sclerosis.

Ehling R, Gassner Ch, Lutterotti A, Strasser-Fuchs S, Kollegger H, Kristoferitsch W, Reindl M, Berger T.

Tissue Antigens. 2004 Jan;63(1):28-33.

PMID:
14651520
44.

Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders.

Reindl M, Khantane S, Ehling R, Schanda K, Lutterotti A, Brinkhoff C, Oertle T, Schwab ME, Deisenhammer F, Berger T, Bandtlow CE.

J Neuroimmunol. 2003 Dec;145(1-2):139-47.

PMID:
14644040

Supplemental Content

Loading ...
Support Center